|Bid||13.83 x 900|
|Ask||14.10 x 900|
|Day's Range||13.51 - 15.02|
|52 Week Range||9.05 - 18.42|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.30|
On average, over time, stock markets tend to rise higher. This makes investing attractive. But if when you choose to...
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indicationsTCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical proof-of-concept for second TCER® molecule IMA402Cash and cash equivalents as well as Other financial assets of $229.1 million1 (€192.8 million) as of June 30, 2021, funding company operations into 2023 Tuebingen, Ger
BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs). T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things.